Member Info for Parob

If GS still have their dregs left to sell (eg that 500K that has just showed up from earlier) and we’ve been rising strongly for 3 days, imagine the effect it will have once they’re fully out.

Having watched the price action very closely for so long, I personally think GS are out.

Just my opinion.

Anyone else notice that no 250K block sales went through today or yesterday?

Yet there’s been the opportunity to sell into volume.

Could it be that GS have finished selling, either keeping the remainder or maybe they’ve been transferred to another party?

Once the chart does turn (and I think we’re getting close), I can see a speedy recovery happening as those waiting on the sidelines for a cheaper price realise we’ve already hit the bottom and scramble to buy in before the long-awaited re-rate.

Bushveld Minerals discuss half year performance, expansion plans and vanadium market outlook

https://tinyurl.com/y54csmp8

11:46 Thu 15 Oct 2020

Bushveld Minerals Ltd's (LON:BMN) Fortune Mojapelo talks to Proactive London's Katie Pilbeam about the company's half year results, which generated revenue of US$43.1mln from its South African vanadium operations.
This performance was down from the US$78mln generated in the same period a year ago due to lower vanadium prices.
Mojapelo also talks through the impact the coronavirus had on production and his optimistic outlook for the next period.

Now there’s a ceasefire, those investors who were holding back (due to the conflict) may now look to enter.

An ascending triangle on the chart was flagged in the one of the Telegram chart groups earlier, so I think we could see a break North out of it this coming week.

GS update.

4 X 250K blocks.

I guesstimate they are down to approx 9.5M shares.

PS: Added a further 60K today.

My current guesstimate based on large sales going through is 10.5M, but as was discussed on the board yesterday, that figure could be lower if some shares have been transferred off market since the last holding TR1 (11/09/20 - RNSd on the 18/9/20).

Interesting that just 2 x 250K blocks were sold yesterday. Daily average has been around the 1M mark. As someone else mentioned yesterday, I haven’t seen any large blocks being sold below 10.5p.

I can’t find the time stamp on them. Can anyone else? They are usually from the previous day.

If so, I may have to revise my guesstimate downwards. GS could be out sooner than any of us think.

Daily update.

1 X 350K
2 X 150K
1 X 250K

Perhaps some of the 100Ks.

I guesstimate that GS are down to approx. 11M shares.

Daily update.

4 X 250K blocks sold today.

I guesstimate GS are down to approx. 12M shares.

Today’s large block sales:

5 X 250K
1 X 400K

Total = 1.65M

So if GS sell 1.5M per day into volume like today, they could be out within two weeks.

On Thursday last week JMC69 posted a rough estimate of how many shares they thought GS had remaining and I had calculated a similar(ish) amount at the time.

Taking today’s large sells into consideration, I guesstimate they are down to about 13M or 14M shares.

A list of products (that I’m aware of) containing Itaconix ingredients:

Clorox Triple Action Dishwasher Detergent:

https://cloroxautodish.com/

Dollar General Ultimate Dishwasher Pacs:

https://www.dollargeneral.com/dg-home-ultimate-dishwasher-pacs-fresh-scent-30-ct.html

Resolve:

https://www.powerofresolve.com/

Greenworks:

https://www.greenworkscleaners.com/

Method:

https://methodhome.com/product-category/home-cleaning/

Dropps:

https://www.dropps.com/products/oxi-booster-pods

Puracy:

https://puracy.com/collections/all

There was a delayed 500K buy that popped up yesterday (from Monday). Wouldn’t surprise me to see more over the coming days.

Taken from AAZ Interims RNS:

We were very pleased to reach agreement and sign heads of terms with Conroy Gold and Natural Resources PLC ("Conroy Gold") to form a joint venture subject to satisfactory due diligence for the exploration and possible mine development in the Longford Down Massif in Ireland. We believe this project has high potential in a transparent and mining-friendly jurisdiction. The Company is currently completing due diligence and finalising the joint venture agreement with Conroy Gold. This process has been impacted slightly due to COVID-19 travel restrictions.

Unilever to drop fossil fuels from cleaning products by 2030
2nd Sept
https://uk.reuters.com/article/uk-climatechange-unilever/unilever-to-drop-fossil-fuels-from-cleaning-products-by-2030-idUKKBN25T0IY
The household goods conglomerate behind the Omo, Cif, Sunlight and Domestos brands said that, instead of petrochemicals, the products would substitute constituents created from plants and other biological sources, marine sources such as algae and waste materials.
Chemicals used in its cleaning and laundry products make up 46% of the company’s Home Care division’s carbon emissions across their lifecyle, and the switch - which Unilever said it is the first company to commit to - will cut those emissions by a fifth.

It has reached the shelves. It’s here:

https://twitter.com/parob17/status/1296328461489930247?s=21

All info here: https://twitter.com/parob17/status/1296328461489930247?s=21

Stuart Ashman, CEO of SkinBioTherapeutics, said:

"We have seen significant positive progress made on the first of our commercial programmes in recent weeks. In such an important scientific milestone, it is reassuring and provides validation of our approach that Sederma has been able to replicate the activity of the SkinBiotix technology and is pushing ahead with the next steps of the project.

"In addition, establishing a clear pathway to commencing a food supplement trial to manage symptoms associated with psoriasis is a great step forward for our collaboration with Winclove. The progress made in such a short period of time is testament to the combined efforts of the SkinBioTherapeutics and Winclove team."

SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company" or "the Group")

Product Development Progress



· Cosmetic programme achieves key scientific milestones with its partner Sederma (Croda)

·Company targeting an accelerated psoriasis food supplement trial in early 2021 to facilitate launch of AxisBiotix product

SkinBioTherapeutics plc (AIM: SBTX), a life science company focused on skin health, provides an update on its product development programmes.



Cosmetic skincare

Sederma, the division of Croda Plc that specialises in the manufacture of bioactive ingredients for the cosmetic industry, has updated the Company on progress of its ongoing collaboration and confirmed that;

· Sederma has successfully replicated the lysate manufacturing process and achieved the same performance from the SkinBiotix® technology as established by the Company

· Sederma is now working to validate scale up of the manufacturing process at different volume levels

· The project is progressing in line with the original plan and has not been adversely impacted by COVID-19.

Sederma will be responsible for the development, manufacture and commercialisation of the SkinBiotix ® technology, with any products resulting from this programme being sold to Croda's global portfolio of Personal Care customers. SkinBioTherapeutics will be paid tiered royalties based on global sales revenues on any licensed products derived from the partnership.



Acceleration of psoriasis food supplement trial

In February 2020, the Company signed a development agreement with Winclove for a probiotic food supplement to help manage the symptoms associated with the skin condition, psoriasis.



In July (RNS 7 July 2020) the Company reported that several months ahead of schedule, Winclove had successfully combined and formulated the blend as a probiotic food supplement, to be known as AxisBiotix ™Ps.



In light of the current restrictions with regards to non-COVID related human studies, the Company has established a protocol for, and is proceeding with, a 'self-managed' food supplement trial.



Participants suffering from mild to moderate psoriasis will be invited to participate in a human study in which they will be provided with samples of AxisBiotix ™Ps to self-administer over an eight week period and track the impact of the food supplement on their skin condition. Participants will submit their findings on a periodic basis through a bespoke mobile device app, thus avoiding the need for clinical attendance. This will accelerate the timing of readout compared to the previously envisaged conventional study. As a result, if the findings are positive, this will allow for a significantly earlier commercial launch than originally planned. The Company anticipates commencing the trial in early 2021.